IMPAACT 2028 is a study to understand children who started treatment very early for HIV, a virus that attacks the body's immune system. It's about learning from kids who got treatment soon after birth to see how they do over a long time. Up to 250 children will be part of this study for about seven years. The study is observational, meaning no treatment is given as part of it. Children in this study were treated with at least three medicines from different classes of ART (Antiretroviral Therapy) within 12 weeks of birth. Some even started treatment within 48 hours. The study helps gather information for future research and collect samples for a special storage called a biorepository. This will aid in future investigations related to HIV cure or remission. Participants need to have HIV-1 infection, be part of previous studies, and their parents must agree to the study terms. They’ll visit the study location every six months for evaluations.

• Study Length: Approximately seven years with check-ups every six months.
• Participants: Up to 250 children who received early HIV treatment.
• Safety: No new treatments are given; it's about observation and sample collection.